Bright Biologics is pleased to announce that its abstract, "The Anti-Tumor Activity of a Novel Anti-HER2 and Anti-c-Met Bispecific Antibody-Drug Conjugate," has been accepted for presentation at the AACR 2025 Annual Meeting, taking place April 25–30 in Chicago, USA.
The novel drug, BB-205, is a first-in-class bispecific antibody-drug conjugate (ADC) designed to target HER2 and c-Met with greater affinity than reference monospecific antibodies. Preclinical studies have shown that BB-205 demonstrates superior efficacy against multiple cancer cell types compared to monospecific ADCs, both in vitro and in vivo. Additionally, in a monkey dose-range finding (DRF) toxicity study, BB-205 was well tolerated at doses up to 5 mg/kg in cynomolgus monkeys.
By simultaneously targeting HER2 and c-Met, BB-205 aims to enhance tumor cell killing while addressing tumor heterogeneity and antigen escape—key challenges in cancer treatment that often lead to tumor relapse.
BB-205 will be presented as a poster on the afternoon of April 28 at AACR 2025.
